Phosphoprotein dynamics of interacting T cells and tumor cells by HySic.
CP: Cancer
CP: Immunology
T cell
cancer
cell-cell interaction
immunology
phosphoproteomics
proteomics
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
26 Dec 2023
26 Dec 2023
Historique:
received:
30
05
2023
revised:
16
09
2023
accepted:
04
12
2023
medline:
27
12
2023
pubmed:
27
12
2023
entrez:
27
12
2023
Statut:
aheadofprint
Résumé
Functional interactions between cytotoxic T cells and tumor cells are central to anti-cancer immunity. However, our understanding of the proteins involved is limited. Here, we present HySic (hybrid quantification of stable isotope labeling by amino acids in cell culture [SILAC]-labeled interacting cells) as a method to quantify protein and phosphorylation dynamics between and within physically interacting cells. Using co-cultured T cells and tumor cells, we directly measure the proteome and phosphoproteome of engaged cells without the need for physical separation. We identify proteins whose abundance or activation status changes upon T cell:tumor cell interaction and validate our method with established signal transduction pathways including interferon γ (IFNγ) and tumor necrosis factor (TNF). Furthermore, we identify the RHO/RAC/PAK1 signaling pathway to be activated upon cell engagement and show that pharmacologic inhibition of PAK1 sensitizes tumor cells to T cell killing. Thus, HySic is a simple method to study rapid protein signaling dynamics in physically interacting cells that is easily extended to other biological systems.
Identifiants
pubmed: 38150364
pii: S2211-1247(23)01610-8
doi: 10.1016/j.celrep.2023.113598
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113598Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests S.I.-M. and D.S.P. are named inventors on patent P097110NL, which is unrelated to this work. D.S.P. is co-founder, shareholder, and advisor of Immagene, which is unrelated to this work. M.A. is currently lead scientific officer for Amigon, which has no relation to this work.